Nuvation Bio Inc
Company Profile
Business description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Contact
1500 Broadway
Suite 1401
New YorkNY10036
USAT: +1 332 208-6102
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
291
Stocks News & Analysis
stocks
What to expect from the January Fed meeting
stocks
Fortescue costs outpace increasing volume
stocks
A top global stock to buy after a big change in its forecast
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,279.30 | 105.10 | 1.15% |
| CAC 40 | 8,131.15 | 11.90 | -0.15% |
| DAX 40 | 24,933.08 | 32.37 | 0.13% |
| Dow JONES (US) | 49,412.40 | 313.69 | 0.64% |
| FTSE 100 | 10,148.85 | 5.41 | 0.05% |
| HKSE | 27,044.86 | 279.34 | 1.04% |
| NASDAQ | 23,601.36 | 100.11 | 0.43% |
| Nikkei 225 | 52,959.62 | 74.37 | 0.14% |
| NZX 50 Index | 13,454.76 | 5.98 | -0.04% |
| S&P 500 | 6,950.23 | 34.62 | 0.50% |
| S&P/ASX 200 | 8,954.20 | 109.10 | 1.23% |
| SSE Composite Index | 4,121.50 | 11.10 | -0.27% |